IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
This study is testing whether combining two drugs, osimertinib and carotuximab, is safe and effective for people with a specific type of advanced lung cancer. The goal is to see if adding carotuximab helps stop tumors from growing when standard treatments are no longer working.
You may be eligible if you have advanced non-small cell lung cancer with a specific EGFR gene mutation that has continued to grow despite previous targeted therapy. Participants must be at least 18 years old and meet specific health criteria regarding past surgeries and other lung conditions.
You will receive both medications and be closely monitored by doctors to determine the safest and most effective dose. The team will perform regular tests, including blood work and imaging, to see how your cancer responds to the new treatment combination.
The study is currently recruiting patients at medical centers in Beverly Hills and Los Angeles, California. Please talk to your oncologist to see if this study is the right fit for your specific health situation.
- 1Tests a new combination of two targeted cancer drugs.
- 2Aims to help patients whose lung cancer has progressed after standard treatment.
- 3Participation includes regular check-ups to ensure the safety and effectiveness of the drugs.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.